Description of patients and laboratory indicators
DM, comorbidity, Gastric ulcer disease, COPD
ISCHAEMIC HEART DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, DIABETES MELLITUS, COPD, IHD, ATRIAL FIBRILLATION
The general characteristics of COVID-19 patients admitted to the day patient facility for antiviral therapy are presented in General patient data.IV, intravenously; IM, intramuscularly; F, female; M, male; BMI, body mass index; mg, milligram, kg, kilogram.Quantitative data are presented as median and interquartile range (Q1-Q3).The frequency of comorbidities in the general group of patients. COPD, Chronic obstructive pulmonary disease; KAT, kidney allotransplantation; IHD, ischaemic heart disease; A-Fib, atrial fibrillation; DM, Diabetes Mellitus; GUD, Gastric ulcer disease. All groups had high levels of comorbidity.All patients were vaccinated with Gam-COVID-Vac. The frequency of vaccination was not significantly different between groups (p = 0.5). The duration between vaccine and mab administration was also not significantly different between groups.Most of the patients were admitted to the day patient facility on Day 3 after the onset of symptoms. During the observation period the condition of the patients in all groups was stable, and the body temperature was in the normal range.SARS-CoV-2 RNA PCR testing showed that 100% patients in the Tixagevimab/Cilgavimab IV groups tested negative at Day 4 of the study regardless of the dose, while 29% of patients in the Regdanvimab group tested positive for SARS-CoV-2 RNA, which was significantly higher (p=0,017) (Testing for SARS-CoV-2 RNA by real-time PCR in nasopharyngeal swabs. IM, intamuscularly; IV, intravenously. SARS-CoV-2 RNA PCR testing showed that 100% patients in the Tixagevimab/Cilgavimab IV groups tested negative at Day 4 of the study regardless of the dose, while 29% of patients in the Regdanvimab group tested positive for SARS-CoV-2 RNA, which was significantly higher.